BHCM
ZVRA icon

Brevan Howard Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Brevan Howard Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$217K Buy
23,324
+8,431
+57% +$76K ﹤0.01% 1847
2025
Q4 		$133K Sell
14,893
-115,858
-89% -$1.1M ﹤0.01% 1654
2025
Q3 		$1.24M Buy
+130,751
New +$1.31M 0.01% 805

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Brevan Howard Capital Management's ZVRA Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Zevra Therapeutics (ZVRA) stake by 57% in Q1 2026, buying an estimated $76K and bringing the position to 23,324 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

Brevan Howard Capital Management first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.24M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Brevan Howard Capital Management held 23,324 shares of Zevra Therapeutics worth $217K as of Q1 2026.
  • Brevan Howard Capital Management bought 8,431 Zevra Therapeutics shares in Q1 2026, an estimated $76K.
  • Zevra Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1847 holding.
  • Brevan Howard Capital Management first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Zevra Therapeutics position peaked at $1.24M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.